Pharmacy Times Continuing Education (PTCE), a leader in continuing education for retail, health-system, managed care, and specialty pharmacists, launches The American Journal of Managed Care (AJMC) Payer and Specialty Pharmacy Forum: Improving the Adoption of Oncology Biosimilars in Practice.
Henlius, a leading biotech company in China developing both biosimilar and innovative biologics, announced today that the European Medicines Agency (EMA) has officially accepted to review the Marketing Authorization Application (MAA) of its trastuzumab biosimilar HLX02.
Yesterday, notable health leaders spoke about the importance of increasing biosimilars to lower health care costs during a POLITICO panel event sponsored by the Biosimilars Forum. Panelists included Congresswoman Diana DeGette (D-CO), Health and Human Services (HHS) official John O’Brien, University of Pittsburgh Professor Inmaculada Hernández, an expert in pharmacy and therapeutics policy, and Leslie Ritter of the National MS Society.
Vizient announces that it is collaborating with Civica Rx to help reduce the impact of drug shortages. By providing insights into purchasing patterns and provider needs through its industry-leading analytics and data capabilities, Vizient will help Civica anticipate gaps in drug availability and affordability.
Sandoz, a Novartis division and a global leader in biosimilars, recently announced data from the Phase III ADMYRA trial demonstrating that the efficacy and safety of biosimilar Hyrimoz (adalimumab) matches that of the reference medicine adalimumab with no clinically meaningful differences in patients with moderate-to-severe rheumatoid arthritis (RA) with inadequate response to disease modifying antirheumatic drugs (DMARDs), including methotrexate (MTX).
Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
As reported by TMR, the global psoriasis treatment market is prognosticated to exhibit a 5.10% CAGR over the forecast period from 2016 to 2024. The market was estimated to be worth US$7.8 bn in 2015 and is forecasted to reach US$12.1 bn by 2024.
The Advisory Council on the Implementation of National Pharmacare’s Final Report highlights the importance of biosimilar medicines in the sustainable implementation of a national pharmacare program.
The Advisory Council on the Implementation of National Pharmacare's Final Report highlights the importance of biosimilar medicines in the sustainable implementation of a national pharmacare program.1
Celltrion Healthcare recently presented new findings at the Annual European Congress of Rheumatology (EULAR 2019) from a two-part study investigating the pharmacokinetics, efficacy and overall safety of CT-P13 SC in patients with RA during the treatment period of one year.
|
|
|
|
|
|
|
|
|